Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968591 | 0.86 | CHRNA1 (0.30) | — | |
| SCHEMBL967770 | 0.86 | CHRNA1 (0.30) | — | |
| SCHEMBL2118460 | 0.86 | BACE1 (0.33) | BACE1CTSDBACE2 | |
| SCHEMBL2108617 | 0.86 | BACE1 (0.33) | BACE1BACE2 | |
| SCHEMBL2107925 | 0.86 | BACE1 (0.33) | BACE1CTSDBACE2 | |
| SCHEMBL2117174 | 0.86 | BACE1 (0.33) | BACE1BACE2 | |
| SCHEMBL2121631 | 0.83 | CHRNA1 (0.35) | ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2108098 | 0.83 | CHRNA1 (0.35) | ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2117414 | 0.83 | CHRNA1 (0.35) | ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL969478 | 0.82 | BACE1 (0.36) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885CTSD 28/4885SCN1A 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.